See more : Xi’an Tianhe Defense Technology Co., Ltd. (300397.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Cortexyme, Inc. (CRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cortexyme, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Public Joint-stock Company “TNS energo Voronezh” (VRSB.ME) Income Statement Analysis – Financial Results
- TSUKADA GLOBAL HOLDINGS Inc. (2418.T) Income Statement Analysis – Financial Results
- Huaneng Power International, Inc. (0902.HK) Income Statement Analysis – Financial Results
- LifeTech Scientific Corporation (LFTSF) Income Statement Analysis – Financial Results
- Nova Leap Health Corp. (NVLPF) Income Statement Analysis – Financial Results
Cortexyme, Inc. (CRTX)
About Cortexyme, Inc.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 60.80M | 61.31M | 30.21M | 10.09M | 9.10M |
| General & Administrative | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Cost & Expenses | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Interest Income | 620.00K | 2.04M | 2.19M | 806.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 957.00K | 1.64M |
| Depreciation & Amortization | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| EBITDA | -90.32M | -78.89M | -39.17M | -11.47M | -10.55M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -89.95M | -78.89M | -39.17M | -12.12M | -10.37M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 373.00K | 2.04M | 2.19M | -357.00K | -1.87M |
| Income Before Tax | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 373.00K | 2.04M | 2.19M | 600.00K | -222.00K |
| Net Income | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.02 | -2.63 | -1.94 | -0.58 | -0.57 |
| EPS Diluted | -3.02 | -2.63 | -1.94 | -0.58 | -0.57 |
| Weighted Avg Shares Out | 29.77M | 29.18M | 19.06M | 21.55M | 21.55M |
| Weighted Avg Shares Out (Dil) | 29.77M | 29.18M | 19.06M | 21.55M | 21.55M |
Cortexyme: The OLE Study Hold Does Not Matter
Cortexyme: The OLE Study Hold Does Not Matter
Cortexyme Stops Enrollment In Mid-Stage Atuzaginstat Study In Alzheimer's Disease
Following the review of hepatic adverse events, the FDA has instituted a partial clinical hold impacting the open-label extension (OLE) phase of Phase 2/3 GAIN trial of Cortexyme Inc (NASDAQ: CRTX) evaluating atuzaginstat (COR388) in patients with mild to moderate Alzheimer's disease. The adverse events were reversible...
Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer's Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (NASDAQ: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer's and other degenerative diseases, received a letter from the U.S. Food and Drug Administration (FDA) stating that a partial clinical hold has been placed on...
Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease on schedule to be announced in Q4 2021 and a pipeline of therapeutics for degenerative diseases, today announced a series of leadership appointments...
Cortexyme: A Fresh Perspective In Alzheimer's
CRTX thinks that a bacteria causes Alzheimer's, and it has research to back up that hypothesis. A Phase 3 trial will yield toppling data in Dec 2021, and they have enough cash.
Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock?
Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.
Cortexyme's Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer's Disease Successfully Advances Past Interim Analysis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseases, today announced that the independent Data Monitoring Committee (DMC) conducted a pre-planned interim analysis and recommended Cortexyme continue...
Cortexyme’s Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer’s Disease Successfully Advances Past Interim Analysis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced that the independent Data Monitoring Committee (DMC) conducted a pre-planned interim analysis and recommended Cortexyme continue...
4,400 Shares in Cortexyme, Inc. (NASDAQ:CRTX) Acquired by TD Asset Management Inc.
TD Asset Management Inc. acquired a new stake in Cortexyme, Inc. (NASDAQ:CRTX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 4,400 shares of the...
Mallinckrodt BLA Submission, And Other News: The Good, Bad And Ugly Of Biopharma
Mallinckrodt reports BLA submission for StrataGraft, fuels merger speculation. Calliditas Therapeutics inks deal for Genkyotex Acquisition.
Source: https://incomestatements.info
Category: Stock Reports